Ravinder Singh1, Aparna Mukherjee1, Mohit Singla1, Bimal Kumar Das2, Sushil Kumar Kabra1, Rakesh Lodha3. 1. Department of Pediatrics, All India Institute of Medical Sciences, Room no. 3061A, New Delhi, 110029, India. 2. Department of Microbiology, All India Institute of Medical Sciences, New Delhi, India. 3. Department of Pediatrics, All India Institute of Medical Sciences, Room no. 3061A, New Delhi, 110029, India. rlodha1661@gmail.com.
Abstract
OBJECTIVE: To evaluate immunological and virological outcomes in human immunodeficiency virus (HIV) infected children at six months of highly active antiretroviral therapy (HAART). METHODS: Records of HIV infected children <15-y-old were reviewed to identify those who were initiated highly active antiretroviral therapy between 2010 and 2014 and had CD4+ T cell percentage and HIV-1 viral load report at baseline visit and after 6 mo of initiation of the treatment. RESULTS: Seventy-four HIV infected children [26% girls, median age IQR 36 (24-108) mo] were included in the study. At the end of six months of HAART, median increase of 11% (6-15%) in CD4+ T cell percentage from the baseline levels was observed; nineteen (26%) children showed an increase in CD4+ T cell percentage of 15% or more at 6 mo. Viral load was undetectable (<47 copies/ml) in 27 (36.4%) children; 21 (28.3%) children had 47- < 500 copies/ml; 16 (21.6%) children had 500- < 10,000 copies/ml and 10 (13.5%) children had ≥10,000 copies/ml. At six months, only 15 (20.2%) children exhibited positive immuno-virological response to HAART (≥ 15% increase in CD4% and <47 HIV-1 RNA copies/ml). CONCLUSIONS: While HAART was effective in improving the immunological and virological parameters in the index cohort of children, virological responses were less robust.
OBJECTIVE: To evaluate immunological and virological outcomes in human immunodeficiency virus (HIV) infectedchildren at six months of highly active antiretroviral therapy (HAART). METHODS: Records of HIV infectedchildren <15-y-old were reviewed to identify those who were initiated highly active antiretroviral therapy between 2010 and 2014 and had CD4+ T cell percentage and HIV-1 viral load report at baseline visit and after 6 mo of initiation of the treatment. RESULTS: Seventy-four HIV infectedchildren [26% girls, median age IQR 36 (24-108) mo] were included in the study. At the end of six months of HAART, median increase of 11% (6-15%) in CD4+ T cell percentage from the baseline levels was observed; nineteen (26%) children showed an increase in CD4+ T cell percentage of 15% or more at 6 mo. Viral load was undetectable (<47 copies/ml) in 27 (36.4%) children; 21 (28.3%) children had 47- < 500 copies/ml; 16 (21.6%) children had 500- < 10,000 copies/ml and 10 (13.5%) children had ≥10,000 copies/ml. At six months, only 15 (20.2%) children exhibited positive immuno-virological response to HAART (≥ 15% increase in CD4% and <47 HIV-1 RNA copies/ml). CONCLUSIONS: While HAART was effective in improving the immunological and virological parameters in the index cohort of children, virological responses were less robust.
Authors: Sam Sophan; Chhour Y Meng; Polidy Pean; Joseph Harwell; Elizabeth Hutton; Sonia Trzmielina; Mohan Somasundaran; Katherine Luzuriaga; David Pugatch Journal: Southeast Asian J Trop Med Public Health Date: 2010-01 Impact factor: 0.267
Authors: J M Franco; J A León-Leal; M Leal; A Cano-Rodriguez; J A Pineda; J Macías; A Rubio; C Rey; B Sanchez; E Lissen Journal: Clin Exp Immunol Date: 2000-03 Impact factor: 4.330
Authors: Philippe R Mutwa; Kimberly R Boer; Brenda Asiimwe-Kateera; Diane Tuyishimire; Narcisse Muganga; Joep M A Lange; Janneke van de Wijgert; Anita Asiimwe; Peter Reiss; Sibyl P M Geelen Journal: PLoS One Date: 2014-11-03 Impact factor: 3.240
Authors: Anand Reddi; Sarah C Leeper; Anneke C Grobler; Rosemary Geddes; K Holly France; Gillian L Dorse; Willem J Vlok; Mbali Mntambo; Monty Thomas; Kristy Nixon; Helga L Holst; Quarraisha Abdool Karim; Nigel C Rollins; Hoosen M Coovadia; Janet Giddy Journal: BMC Pediatr Date: 2007-03-17 Impact factor: 2.125